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According to the World Health Organization
(WHO 2007), 80 million people worldwide
are afflicted with chronic obstructive pul-
monary disease (COPD), and 3 million died
from COPD in 2005. The WHO also pre-
dicts that COPD will be the fourth leading
cause of death globally by 2030. Recent atten-
tion has focused on evaluating the relationship
between pulmonary function and cadmium
body burden and the possible role of cad-
mium in the development of pulmonary
diseases such as COPD and emphysema.
Cadmium is a trace element that has no
nutritive function in humans (Newman-
Taylor 1998), and it is a probable lung car-
cinogen in humans according to the Agency
for Toxic Substances and Disease Registry
(ATSDR 1999) Toxicological Profile for
Cadmium. The toxicity of cadmium in the
lungs has been well documented in animal
studies. For example, cadmium inhalation pro-
duces a pulmonary inﬂammatory response in
mammals (Kirschvink et al. 2006), and daily
doses of 1.6 mg/m3 cadmium aerosol over a
6-week period were associated with acute pul-
monary damage and emphysema in rats (Hart
1986). Thus, pulmonary toxicity studies in
animals support the hypothesis that reduced
lung function among smokers may be partially
attributable to cadmium in cigarette smoke.
Primary nonoccupational sources of cadmium
exposure within the general population include
ingestion of contaminated food (Järup et al.
1998; Kido et al. 1992) and inhalation of ciga-
rette smoke (Järup et al. 1998; Satarug and
Moore 2004), and smokers have higher body
burdens of cadmium than nonsmokers (Erzen
and Kragelj 2006; Grasseschi et al. 2003; Järup
et al. 1998; Mutti et al. 2006).
Although previous studies have examined
the association between pulmonary function
and cadmium exposure in animals (Hart 1986;
Kirschvink et al. 2006; Lai and Diamond
1992) and in occupationally exposed cohorts
(Cortona et al. 1992; Davison et al. 1988;
Edling et al. 1986; Elinder 1986; Jakubowski
et al. 2004; Lauwerys et al. 1979; Nordberg
2004; OSHA 1993; Sakurai et al. 1982; Smith
et al. 1976; Stanescu et al. 1977), few studies
have evaluated the association between cad-
mium exposure and pulmonary function in
the general population. 
A recent study evaluated the effects of
cadmium exposure (measured by individual
spot urinary concentrations) on pulmonary
function among participants in the Third
National Health Examination and Nutrition
Examination Survey (NHANES III) (Mannino
et al. 2004). Forced vital capacity (FVC),
forced expiratory volume in 1 sec (FEV1),
FEV1/FVC ratio, and a diagnosis of the
Global Initiative on Obstructive Lung Disease
(GOLD) stage II or higher COPD (deﬁned as
FEV1/FVC ratio < 0.7 and FEV1 < 80% pre-
dicted) were all inversely correlated with uri-
nary cadmium concentrations in current and
former smokers but not in nonsmokers
(Mannino et al. 2004). The Mannino study
was crucial in that it was the ﬁrst to evaluate
the relationship between cadmium body bur-
den and pulmonary function using a quantiﬁ-
able biomarker of exposure. Urinary cadmium
is influenced by body burden and increases
with age (Järup et al. 1998) and in proportion
to the accumulated amount in the body
(Elinder 1986), and urinary cadium is
therefore generally recognized as an effective
exposure surrogate. 
The aim of this study was to examine the
association between pulmonary function and
cadmium body burden in a subcohort of the
Normative Aging Study (NAS) while using
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BACKGROUND: High levels of cadmium exposure are known to cause emphysema in occupationally
exposed workers, but little has been reported to date on the association between chronic environ-
mental cadmium exposure and pulmonary function. 
OBJECTIVE: In this study we examined the association between pulmonary function and cadmium
body burden in a subcohort of the Normative Aging Study, a community-based study of aging.
METHODS: We examined 96 men who had cadmium measured in single 24-hr urinary specimens
collected in 1994–1995 and who had one to three tests of pulmonary function between 1994 and
2002 (a total of 222 observations). We used mixed-effect models to predict pulmonary function
based on individual 24-hr urinary cadmium output, adjusted for age, height, time elapsed from the
baseline, and smoking status. We assessed effect modiﬁcation by smoking status. 
RESULTS: Among all subjects, a single log-unit increase in baseline urinary cadmium was inversely
associated with forced expiratory volume in 1 sec (FEV1) percent predicted [β = –7.56%; 95% con-
fidence interval (CI) –13.59% to –1.53%]; forced vital capacity (FVC) percent predicted (β =
–2.70%; 95% CI –7.39% to 1.99%), and FEV1/FVC ratio (β = –4.13%; 95% CI –7.61% to
–0.66%). In models including an interaction between urinary cadmium and smoking status, there
was a graded, statistically signiﬁcant reduction in FEV1/FVC ratio across smoking status in associa-
tion with urinary cadmium. 
CONCLUSIONS: This study suggests that chronic cadmium exposure is associated with reduced pul-
monary function, and cigarette smoking modiﬁes this association. These results should be interpreted
with caution because the sample size is small, and further studies are needed to conﬁrm our ﬁndings. 
KEY WORDS: cadmium, cigarette smoking, forced expiratory volume, forced vital capacity,
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measurements to control for subject-specific
variation and to reduce residual confounding
associated with subject age and time.
Methods
Study population. The NAS consists of a cohort
of 2,280 healthy male volunteers from Boston,
Massachusetts. Participants were mostly white,
21–80 years of age, and free of heart disease,
hypertension, diabetes mellitus, cancer, peptic
ulcer, gout, recurrent asthma, bronchitis, or
sinusitus at the beginning of the study in 1961
(Bell et al. 1972). Since entry, participants have
had regular medical screenings every 3–5 years
consisting of a physical examination, blood and
urine tests, and pulmonary function testing
(Litonjua et al. 2005). In this study we analyzed
a randomly selected subcohort of 96 NAS par-
ticipants whose urinary cadmium was measured
for a separate study assessing the relationship
between urinary cadmium and dietary intake.
All 96 participants had a 24-hr urinary specimen
(collected between March 1994 and November
1995) and met the following criteria: a) subject’s
24-hr urine volume collected was ≥ 3,000 mL,
b) no urine was spilled during collection, c) sub-
ject’s creatinine clearance was ≥ 50 in order to
exclude subjects with poor renal function, and
d) the subject had complete information on
dietary intake. 
Participants visited the study center in the
morning after abstaining from smoking.
Physical examinations included measurement
of height, weight, and lung function (FVC,
FEV1) testing. We assessed smoking status
and intensity (pack-years of cigarettes) using
the American Thoracic Society Division of
Lung Diseases 1978 questionnaire (Ferris
1978). All participants provided written
informed consent. This study was reviewed
and approved by the institutional review
boards of all participating institutions.
Pulmonary function testing. All pul-
monary tests were performed according to
American Thoracic Society standard method-
ology (ATS 1987). Each subject made up to
eight FVC maneuvers to obtain three accept-
able curves according to predefined criteria,
and standard methods were used to obtain
FVC and FEV1 (Litonjua et al. 2005). We
used the largest value of the three maneuvers
for either measure (not necessarily from the
same curve) for this analysis, and all values
were corrected to body temperature and pres-
sure saturated with water vapor (Litonjua et al.
2005). Pulmonary function data including
FEV1 and FVC measurements between 1994
and 2002 were available for all 96 subjects, for
a total of 222 observations (3 measurements
for 46 subjects; 2 measurements for 34 sub-
jects; 1 measurement for 16 subjects). The
mean duration between successive pulmonary
tests was approximately 3.1 years. 
We calculated FEV1 and FVC as the
percentage of predicted values using the
prediction equations from NHANES III
(Hankinson et al. 1999). For white males
≥ 20 year of age, the following equations are
suggested:
FEV1 % predicted 
= 100 × [0.5536 – 0.01303 × Age
– 0.000172 × Age2
+ 0.00014098 × Height2 (cm2)] [1]
FVC % predicted 
= 100 × [–0.1933 + 0.00064 × Age 
– 0.000269 × Age2
+ 0.00018642 × Height2 (cm2)]. [2]
Urinary cadmium analysis. For each sub-
ject, urinary cadmium samples and pulmonary
function tests were given on the same date dur-
ing between March 1994 and November
1995. All urine samples were handled in a
class-100 clean hood. All glassware and plastics
were cleaned by soaking in 10% nitric acid
(HNO3) for 24 hr and rinsing several times
with deionized water. Reagents used in this
study were HNO3 (Optima; Seastar Chemical
Co., Pittsburgh, PA); National Institute of
Standard and Technology Standard Reference
Material (NIST SRM) 1643d (Gaithersburg,
MD); enriched isotope spike 113Cd (Oak
Ridge National Laboratory, Oak Ridge, TN).
We mixed 5 mL of urine sample with 1 mL of
isotope dilution spike (40 ppb 113Cd-enriched
isotope dilution spike) and 20 μL of chelating
resin [10% SPR-IDA (suspended particulate
reagent–iminodiacetate), 10 μL; CETAC
Technologies (Omaha, NE)] in a plastic cen-
trifuge tube. After adjusting the pH of the
solution to 8, samples were centrifuged at
5,000 rpm for 20 min. Supernatant was dis-
carded and resin was washed with deionized
water adjusted to a pH of 8. Then 2 mL of 5%
HNO3 was added to the precipitate, and it was
centrifuged at 5,000 rpm for 20 min. The cad-
mium-containing supernatant was then
removed and analyzed by inductively coupled
plasma mass spectrometry (Sciex Elan 5000;
PerkinElmer, Norwalk, CT), with standard
instrument operating and data collection para-
meters, using the isotope dilution procedure.
Quality control and quality assurance proce-
dures included analyses of procedural blanks,
duplicate analysis, spiked samples, and analy-
sis of NIST SRM 2670 (toxic metals in
freeze-dried urine), and NIST SRM 1643d
(trace elements in water) to monitor the accu-
racy and recovery rates of the procedure for
each analytic batch. We report results as the
average of five replicate measurements.
Recoveries of these quality control standards
were between 90% and 110% in our labora-
tory. The calculated detection limit for Cd
analysis by this procedure was 0.02 ng/mL of
sample (urinary Cd for all 96 samples > 0.02
ng/mL). Urinary cadmium measurements
used in this study were adjusted for individual
24-hr urine output.
Statistical analysis. Statistical analysis was
carried out using SAS (version 9.1; SAS
Institute Inc., Cary, NC), and the primary out-
come measures were FEV1 percent predicted,
FVC percent predicted, and FEV1/FVC ratio.
We log-transformed 24-hr urinary cadmium
outputs (U-Cd) to normalize the distribution.
Because our pulmonary function outcomes
were measured repeatedly, we fit a mixed-
effects models using the PROC MIXED
procedure in SAS to deal with lack of indepen-
dence of observations. For FEV1/FVC ratio,
we considered the following covariates: base-
line age (years), baseline height (cm), time
elapsed from the baseline (years), and smoking
status [never smokers, former smokers with
low pack-years (≤ 30), former smokers with
high pack-years (> 30), and current smokers],
where baseline is deﬁned as the time point of
urinary cadmium and pulmonary function
measurements during the period between
March 1994 and November 1995. For FEV1
percent predicted and FVC percent predicted,
baseline age and height were not included
because the percentage of predicted value
already accounts for age and height. Because
smoking status is the only time-dependent
variable, the interaction between time and
smoking status was included. We also included
an interaction between time and urinary cad-
mium in the model to test whether the associa-
tion between urinary cadmium and lung
functions changes over time. A random slope
for the time elapsed from the baseline was ini-
tially considered to account for subject-speciﬁc
variability of lung function over time, but a
random intercept-only model was preferred
based on the likelihood ratio test comparing
the two models. The following equation
describes the structure of our ﬁtted models:
Yij = (b0 + ui) + covariates + b1Timeij
+ b2log(U-Cd)ij
+ b3Time × log(U-Cd)ij + eij, [3]
where Yij is the lung function in subject i at
time j, b0 is the overall intercept, ui is the sep-
arate random intercept for subject i, b1 is the
slope representing the overall effect of time,
b2 is the slope representing the overall effect
of log-transformed U-Cd, and b3 is the slope
for the interaction between time and U-Cd.
As a sensitivity analysis, we also re-ran the
same mixed models using raw lung function
measures (FEV1 and FVC, in liters) further
adjusted for baseline age and height. 
To evaluate effect modification by
smoking status, we introduced an interaction
term between categories of smoking status
Urinary cadmium and pulmonary function
Environmental Health Perspectives • VOLUME 116 | NUMBER 9 | September 2008 1227and log-transformed U-Cd, and tests for lin-
ear trend of U-Cd across the four categories
of smoking status were computed. 
Results
Geometric mean 24-hr urinary cadmium out-
put and mean pulmonary function measure-
ments at baseline stratiﬁed by age, height, and
smoking status are presented in Table 1.
Current smokers had a higher geometric mean
U-Cd and a lower mean FEV1/FVC ratio
than both former smokers and never smokers,
and former smokers who reported smoking
> 30 pack-years had a higher mean U-Cd and
a lower mean FEV1/FVC ratio than both for-
mer smokers reporting ≤ 30 pack-years and
never smokers (p-values for trend < 0.05). 
Table 2 shows the adjusted regression results
of the main effects models of U-Cd with FEV1
percent predicted, FVC percent predicted, or
FEV1/FVC ratio as the primary outcome meas-
urement. Among all subjects, a single log-unit
increase in U-Cd was inversely associated with
FEV1 percent predicted [β = –7.56%; 95%
conﬁdence interval (CI), –13.59 to –1.53%],
FVC percent predicted (β = -2.70%; 95% CI,
–7.39 to 1.99%), and FEV1/FVC ratio (β =
–4.13%; 95% CI, –7.61 to –0.66%) at base-
line after adjusting for potential confounders.
No statistically signiﬁcant interactions between
log U-Cd and time were found. The main-
effects models also showed that current smok-
ers had borderline significantly lower FEV1
percent predicted (β = –10.70%; 95% CI,
–21.40 to 0.00) compared with never smokers,
and there was a gradual reduction in FEV1 per-
cent predicted across categories of smoking sta-
tus (p-value for trend = 0.07). Additionally,
there was a marginally significant increasing
trend in FEV1/FVC ratio decline over time
across categories of smoking status (p-value for
trend = 0.08). The models using raw FEV1
and FVC measured in liters additionally
adjusted for baseline age and height gave simi-
lar results to those found using the percentage
of predicted values (data not shown). 
We assessed whether smoking status mod-
ified the effect of U-Cd on lung function
(Figure 1). Because the interaction between
log U-Cd and time was not statistically signif-
icant, this term was excluded when we tested
the interaction between U-Cd and smoking
status. A log-unit increase in urinary cad-
mium output was associated with –0.90%
(95% CI, –5.37 to 3.58%), –6.22% (95%
CI, –13.87 to 1.44%), –10.06% (95% CI,
–16.49 to –3.64%), and –9.97% (95% CI,
–19.60 to –0.34%) in FEV1/FVC ratio
among never smoker, former smokers with
low pack-years, former smokers with high
pack-years, and current smokers, respectively.
For FEV1/FVC ratio, there was a trend of
increasing magnitude of effect of U-Cd on
pulmonary function with increasing smoking
status category (p-value for trend = 0.03). The
same trend was seen for FEV1 percent pre-
dicted, with the largest effect of U-Cd among
former smokers with greater than 30 pack-
years. The effect of U-Cd among current
smokers was comparable but slightly weaker
(p-value for trend = 0.28). In contrast, U-Cd
was not significantly associated with FVC
percent predicted, and smoking status did not
seem to modify the association between U-Cd
and FVC in our cohort. 
Discussion
In this study cohort, U-Cd was significantly
associated with lower FEV1 as the percentage
of predicted values and FEV1/FVC ratio after
adjustment for potential confounders. We
also observed a signiﬁcant trend of increased
effect of U-Cd on pulmonary function, espe-
cially FEV1/FVC ratio, with increasing smok-
ing status category. However, U-Cd was not
associated with the rate of change in lung
function over the period of observation.
This finding is consistent with a cross-
sectional study on urinary cadmium body bur-
den and pulmonary function using data from
NHANES III (Mannino et al. 2004). Other
studies that have examined this association in
human populations have been primarily con-
cerned with occupational exposure, and the
results are somewhat inconsistent. For exam-
ple, inverse associations between occupational
exposure to cadmium and pulmonary function
have been suggested in several studies (Davison
et al. 1988; Edling et al. 1986; Jakubowski
et al. 2004; Nordberg 2004; Sakurai et al.
1982; Smith et al. 1976), but the effect esti-
mates of cadmium exposure on pulmonary
function and the methods used among these
studies varied widely, making it difficult to
confirm a definitive dose–response relation-
ship. In addition, other occupational studies of
cadmium exposure and pulmonary function
have found no such association (Cortona et al.
1992; Lauwerys et al. 1979; Stanescu et al.
1977), although some of these latter studies
Lampe et al.
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Table 1. Frequency distributions, geometric mean 24-hr urinary cadmium outputs, and mean pulmonary
function measurements at baseline stratiﬁed by age, height, and smoking status (n = 96).
24-hr U-Cd FEV1 FVC FEV1/FVC ratio
Variable No. (%) (ng)a (% predicted)b (% predicted)b (%)b
Baseline age (years)
< 65 36 (37.5) 615.5 (1.9) 95.3 (14.8) 91.9 (12.3) 78.3 (7.2)
65–70 26 (27.1) 566.9 (2.2) 91.2 (17.4) 90.8 (13.4) 74.2 (8.2)
> 70  34 (35.4) 577.2 (1.8) 92.3 (20.9) 87.0 (12.8) 76.4 (12.2)
p for trend 0.68 0.48 0.11 0.39
Baseline height (cm)
< 170 28 (29.2) 573.1 (2.0) 98.4 (14.4) 91.9 (10.3) 78.9 (8.6)
170–180 26 (27.1) 585.9 (2.1) 91.3 (18.6) 90.1 (13.7) 72.5 (11.3)
> 180 42 (43.8) 600.4 (1.8) 89.6 (19.2) 85.0 (13.6) 77.4 (8.4)
p for trend 0.93 0.08 0.13 0.43
Smoking status
Never 35 (36.5) 394.3 (2.0) 97.5 (16.8) 91.8 (12.5) 78.6 (8.9)
Former (0–30 pack-years) 32 (33.3) 621.5 (1.5) 97.7 (15.3) 92.8 (11.2) 77.9 (8.4)
Former (> 30 pack-years) 18 (18.8) 766.0 (1.8) 86.3 (18.3) 83.8 (12.6) 75.3 (11.8)
Current 11 (11.5) 1165.0 (1.6) 77.5 (15.7) 85.3 (15.7) 67.8 (6.2)
p for trend < 0.001 < 0.001 0.027 0.002
aGeometric mean (geometric SD). bArithmetic mean (SD).
Table 2. Adjusted estimates (95% conﬁdence intervals) for FEV1 percent predicted, FVC percent predicted,
and FEV1/FVC ratio from the main effects models of urinary cadmium.a
Characteristic FEV1 (% predicted) FVC (% predicted) FEV1/FVC ratio (%)
Intercept 142.2 (105.7 to 178.6) 107.6 (79.28 to 136.0) 130.0 (67.50 to 192.6)
Baseline age (years) — — –0.03 (–0.33 to 0.26)
Baseline height (cm) — — –0.14 (–0.45 to 0.16)
Smoking status
Never Referent Referent Referent
Former (0–30 pack-years) 3.63 (–4.77 to 12.04) 2.01 (–4.49 to 8.52) 1.54 (–3.30 to 6.39)
Former (> 30 pack-years) –6.83 (–16.58 to 2.92) –5.33 (–13.03 to 2.37) –1.30 (–7.03 to 4.42)
Current –10.70 (–21.40 to 0.00) –7.00 (–16.07 to 2.06) –3.17 (–9.64 to 3.31)
Time elapsed from the baseline (years) 1.00 (–1.90 to 3.90) –0.12 (–3.74 to 3.51) 0.94 (–1.29 to 3.17)
Smoking × time
Never Referent Referent Referent
Former (0–30 pack-years) 0.49 (–0.19 to 1.17) 0.29 (–0.56 to 1.14) 0.06 (–0.46 to 0.58)
Former (> 30 pack-years) –0.55 (–1.46 to 0.36) 0.15 (–0.98 to 1.28) –0.47 (–1.16 to 0.23)
Current –0.32 (–1.76 to 1.11) 1.15 (–0.62 to 2.92) –1.07 (–2.16 to 0.03)
LogU-Cd (ng) –7.56 (–13.59 to –1.53) –2.70 (–7.39 to 1.99) –4.13 (–7.61 to –0.66)
LogU-Cd × time –0.19 (–0.67 to 0.29) –0.10 (–0.70 to 0.50) –0.11 (–0.47 to 0.26)
aSample size = 96 subjects, 222 pulmonary function observations, with a maximum of 3 pulmonary function observations
per subject.did not control for smoking status among their
study groups, raising methodological issues
(Elinder 1986). Despite these uncertainties, it
remains generally accepted that chronic expo-
sure to cadmium fumes in the workplace is a
risk factor for reduced pulmonary function
(Elinder 1986; Occupational Safety and
Health Administration 1993), supporting the
hypothesis that environmental cadmium expo-
sure may be a significant contributor to
reduced pulmonary function among smokers.
Animal studies also support a link between
cadmium exposure and reduced pulmonary
function. For example, rats exposed to cad-
mium aerosol at a concentration of 1.6 mg/m3
for 2 weeks had increased leukocyte concentra-
tions and alveolar thickening in the lung (Hart
1986). The administration of three intratra-
cheal injections of cadmium chloride over a
5-day period was associated with decreased
lung capacity and increased alveolar wall thick-
ness in rats (Lai and Diamond 1992). Further-
more, repeated 1-hr exposures to 0.1%
cadmium chloride for 3 weeks led to higher
bronchoalveolar lavage ﬂuid concentrations of
macrophages and neutrophils in rats, as well as
to decreased levels of glutathione during the
ﬁrst week of exposure (Kirschvink et al. 2006).
These results suggest that cadmium exposure
can lead to an acute inflammatory reaction
accompanied by a buildup of free radicals (evi-
denced by decreased glutathione levels), which
can consequently lead to lung inflammation
(Kirschvink et al. 2006). Thus, in animals cad-
mium is associated with physiological changes
indicative of reduced pulmonary function.
We observed a dose-dependent relation-
ship between urinary cadmium and FEV1/
FVC ratio with increasing smoking status cate-
gory. It has previously been shown that smok-
ers have higher body burdens of cadmium
compared with nonsmokers, which may
explain why the strength of the association
between urinary cadmium and pulmonary
function depends on smoking intensity (Lewis
et al. 1972). However, because urinary cad-
mium was associated with pulmonary function
even after adjusting for smoking status, smok-
ing factors alone cannot explain the associa-
tion. The cadmium in cigarette smoke may
exert a toxic effect that is independent of the
combined effects of the non-cadmium
elements of cigarette smoke.
It was also surprising that we did not ﬁnd
a strong association between 24-hr U-Cd and
FVC. Although the NHANES III study did
find an inverse association between creati-
nine-adjusted urinary cadmium and FVC
(Mannino et al. 2004), the association was
weaker than that between urinary cadmium
and FEV1. It is possible that, due to sample
size (n = 96), we did not have the statistical
power to detect the association between
urinary cadmium and FVC.
We also did not ﬁnd any suggestion of an
effect among nonsmokers. One potential
explanation is that cadmium’s effect on lung
function requires airborne exposure and pul-
monary deposition, a possibility also noted by
Hendrick (2004) when commenting on the
same phenomenon in Mannino et al.’s (2004)
study of cadmium and lung function in
NHANES III data. An alternative explana-
tion, as Hendrick points out, is that cadmium
body burden may simply be a passive marker
of exposure to cigarette smoke and unrelated
to the decrements in lung function seen
among current and former smokers in our
study. However, because there was a signifi-
cant effect of cadmium on lung function even
after controlling for smoking status, the
results are consistent with an independent
effect of cadmium. In addition, although
smoking would clearly be the dominant
source of airborne cadmium exposure to any
given individual, it is well known that cad-
mium content varies widely among cigarettes
(depending on cadmium levels in soil used to
grow tobacco, methods of processing, and the
like) (Yue 1992), which may explain why we
would see an effect of cadmium on lung func-
tion that is independent from an effect of
smoking. Unfortunately, our study does not
answer the question of whether other metals
that occur in cigarette smoke, such as lead
and aluminum, may enhance the effect of
cadmium on lung function. Mutti et al.
(2006) demonstrated that these elements
are abundant along with cadmium in the
exhaled breath condensate of current smokers.
Cadmium and lead both have mechanisms of
toxicity that could result in the physiological
changes that cause reduced lung function:
Cadmium inhibits the production of connec-
tive tissue in the lungs, and lead may cause
glutathione depletion in the lungs (Mutti
et al. 2006). It cannot be ruled out, therefore,
that these two effects (as well as others) may
be acting in tandem to result in the decre-
ments in lung function seen among the
subjects in this study.
In the NHANES III study, urinary cad-
mium concentrations were adjusted for creati-
nine concentration (Mannino et al. 2004). In
this study, creatinine-adjusted urine concentra-
tions were not used because we had more com-
plete data on 24-hr urinary output and thus we
adjusted urinary cadmium for total urinary
output instead. Adjustment for urinary creati-
nine is required for spot samples because of
concentration dilution of urine, but creatinine
adjustment may not be necessary for 24-hr
urine samples (Berlin et al. 1985). The use of
certain methods for the adjustment of urinary
cadmium output for hydration status may also
inﬂuence the effect of smoking status on uri-
nary cadmium and pulmonary function. 
In this study, most subjects had multiple
time points of pulmonary function data,
which allowed us to reduce the effect of
within-subject variability in pulmonary func-
tion over time. It also helped us to explore
time-dependent behavior of smoking status in
the model and eliminate any trend effects due
to time that are not accounted for by the other
variables. However, there were some limita-
tions to this study. First, our study cohort was
small (n = 96) compared with similar analyses
drawn from large-scale cohort studies such as
NAS and NHANES III, and thus our statisti-
cal power is comparatively low. Second,
although we had repeated pulmonary function
data, we only had one valid time point
(1994–1995) of urinary cadmium data per
subject. Thus, we had to assume that the 24-hr
urinary cadmium outputs from 1994–1995
were representative of the actual 24-hr urinary
cadmium outputs for the entire time
(1994–2002) during which pulmonary data
were collected. This might be a reason that we
did not ﬁnd a signiﬁcant association of urinary
cadmium with the rate of change in lung
function. In addition, we had only at most
three measurements of lung function per sub-
ject, so we may not have the power to detect
such an association. Third, we cannot say
whether high urinary cadmium output physio-
logically precedes decrements in pulmonary
Urinary cadmium and pulmonary function
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Figure 1. Estimated change (95% confidence interval) in FEV1 percent predicted, FVC percent predicted,
and FEV1/FVC ratio for every log-unit increase in 24-hr urinary cadmium output by smoking status. pkyr,
pack-years. Each model was adjusted for smoking status, time elapsed from the baseline, and the interac-
tion between smoking status and time. FEV1/FVC ratio model was also adjusted for baseline age and
height. The p-values above each pulmonary function are for tests for trend (n = 96 subjects, 222 pulmonary
function observations, with a maximum of 3 pulmonary function observations per subject). 
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function over time because there was not a
long enough follow-up period between uri-
nary cadmium measurement and pulmonary
testing to make that kind of causal inference.
Fourth, we lacked data on urinary cotinine
levels and therefore we did not have an objec-
tive measurement of smoking intensity.
Finally, we lacked precise data on the duration
of time since quitting among the cohort of
former smokers in our study, so we were
unable to take into consideration that former
smokers may differ in susceptibility to the
effects of cadmium exposure depending on
how long they have abstained from smoking.
In conclusion, we found significant evi-
dence that there exists an inverse association
between baseline cadmium body burden and
pulmonary function, but the association does
not change over time. Our results also suggest
that cigarette smoking modifies this associa-
tion. However, the present study should be
interpreted with caution because of the small
sample size; further studies with a larger sam-
ple size as well as a longitudinal design are
needed to conﬁrm our ﬁndings. The availabil-
ity of more complete information on cigarette
smoking, such as plasma cotinine levels, may
also help elucidate the effect of smoking sta-
tus on the association between cadmium
exposure and pulmonary function.
REFERENCES
American Thoracic Society. 1987. Standardization of spirome-
try—1987 update. Statement of the American Thoracic
Society. Am Rev Respir Dis 136(5):1285–1298.
ATSDR. 1999. Toxicological Profile for Cadmium. Atlanta,
GA:Agency for Toxic Substances and Disease Registry.
Available: http://www.atsdr.cdc.gov/toxprofiles/tp5.html
[accessed 16 March 2008].
Bell B, Rose C, Damon A. 1972. The Normative Aging Study: an
interdisciplinary and longitudinal study of health and
aging. Aging Human Dev 3:4–17.
Berlin A, Alessio L, Sesana G, Dell’Orto A, Ghezzi I. 1985.
Problems concerning the usefulness of adjustment of uri-
nary cadmium for creatinine and speciﬁc gravity. Int Arch
Occup Environ Health 55(2):107–111.
Cortona G, Apostoli P, Toffoletto F, Baldasseroni A, Ghezzi I,
Goggi E, et al. 1992. Occupational exposure to cadmium
and lung function. IARC Sci Publ 118:205–210.
Davison AG, Fayers PM, Taylor AJ, Venables KM, Darbyshire J,
Pickering CA, et al. 1988. Cadmium fume inhalation and
emphysema. Lancet 1(8587):663–667.
Edling C, Elinder CG, Randma E. 1986. Lung function in workers
using cadmium containing solders. Br J Ind Med
43(10):657–662.
Elinder C. 1986. Respiratory effects. In: Cadmium and Health: A
Toxicological and Epidemiological Appraisal: Effects and
Response (Friberg L, Elinder C, Kjellstrom T, Nordberg GF,
eds). Boca Raton, FL:CRC Press, Inc.
Erzen I, Kragelj LZ. 2006. Cadmium concentrations in blood in a
group of male recruits in Slovenia related to smoking
habits. Bull Environ Contam Toxicol 76(2):278–284.
Ferris BG. 1978. Epidemiology Standardization Project
(American Thoracic Society). Am Rev Respir Dis 118(6 pt
2):1–120.
Grasseschi RM, Ramaswamy RB, Levine DJ, Klaassen CD,
Wesselius LJ. 2003. Cadmium accumulation and detoxifi-
cation by alveolar macrophages of cigarette smokers.
Chest 124(5):1924–1928.
Hankinson JL, Odencrantz JR, Fedan KB. 1999. Spirometric ref-
erence values from a sample of the general U.S. popula-
tion. Am J Respir Crit Care Med 159(1):179–187.
Hart BA. 1986. Cellular and biochemical response of the rat
lung to repeated inhalation of cadmium. Toxicol Appl
Pharmacol 82(2):281–291.
Hendrick DJ. 2004. Smoking, cadmium, and emphysema.
Thorax 59(3):184–185.
Jakubowski M, Abramowska-Guzik A, Szymczak W, Trzcinka-
Ochocka M. 2004. Influence of long-term occupational
exposure to cadmium on lung function tests results. Int J
Occup Med Environ Health 17(3):361–368.
Järup L, Berglund M, Elinder CG, Nordberg G, Vahter M. 1998.
Health effects of cadmium exposure—a review of the lit-
erature and a risk estimate. Scand J Work Environ Health
24(suppl 1):1–51.
Kido T, Nogawa K, Ohmichi M, Honda R, Tsuritani I, Ishizaki M,
et al. 1992. Signiﬁcance of urinary cadmium concentration
in a Japanese population environmentally exposed to cad-
mium. Arch Environ Health 47(3):196–202.
Kirschvink N, Martin N, Fievez L, Smith N, Marlin D, Gustin P.
2006. Airway inflammation in cadmium-exposed rats is
associated with pulmonary oxidative stress and emphy-
sema. Free Radic Res 40(3):241–250.
Lai YL, Diamond L. 1992. Cigarette smoke exposure does not
prevent cadmium-induced alterations in rat lungs.
J Toxicol Environ Health 35(1):63–76.
Lauwerys RR, Roels HA, Buchet JP, Bernard A, Stanescu D.
1979. Investigations on the lung and kidney function in
workers exposed to cadmium. Environ Health Perspect
28:137–145.
Lewis GP, Coughlin LL, Jusko WJ, Hartz S. 1972. Contribution of
cigarette smoking to cadmium accumulation in man.
Lancet 1(7745):291–292.
Litonjua AA, Lazarus R, Sparrow D, Demolles D, Weiss ST.
2005. Lung function in type 2 diabetes: the Normative
Aging Study. Respir Med 99(12):1583–1590.
Mannino DM, Holguin F, Greves HM, Savage-Brown A, Stock
AL, Jones RL. 2004. Urinary cadmium levels predict lower
lung function in current and former smokers: data from the
Third National Health and Nutrition Examination Survey.
Thorax 59(3):194–198.
Mutti A, Corradi M, Goldoni M, Vettori MV, Bernard A,
Apostoli P. 2006. Exhaled metallic elements and serum
pneumoproteins in asymptomatic smokers and patients
with COPD or asthma. Chest 129(5):1288–1297.
Newman-Taylor AJ. 1998. Cadmium. In: Environmental and
Occupational Medicine (Rom WN, ed). Philadelphia:
Lippincott-Raven Publishers.
Nordberg GF. 2004. Cadmium and health in the 21st century—
historical remarks and trends for the future. Biometals
17(5):485–489.
Occupational Safety and Health Administration. 1993.
Occupational exposure to cadmium. Fed Reg 58:21778–21850.
Available: http://www.osha.gov/pls/oshaweb/owadisp.show_
document?p_id=13294&p_table=FEDERAL_REGISTER
[accessed 14 January 2008].
Sakurai H, Omae K, Toyama T, Higashi T, Nakadate T. 1982. Cross-
sectional study of pulmonary function in cadmium alloy work-
ers. Scand J Work Environ Health 8(suppl 1):122–130.
Satarug S, Moore MR. 2004. Adverse health effects of chronic
exposure to low-level cadmium in foodstuffs and cigarette
smoke. Environ Health Perspect 112:1099–1103.
Smith TJ, Petty TL, Reading JC, Lakshminarayan S. 1976.
Pulmonary effects of chronic exposure to airborne cad-
mium. Am Rev Respir Dis 114(1):161–169.
Stanescu D, Veriter C, Frans A, Goncette L, Roels H, Lauwerys
R, et al. 1977. Effects on lung of chronic occupational
exposure to cadmium. Scand J Respir Dis 58(6):289–303.
WHO. 2007. Chronic Obstructive Pulmonary Diseases. Geneva:
World Health Organization. Available: http://www.who.int/
respiratory/copd/en/ [accessed 18 February 2007].
Yue L. 1992. Cadmium in tobacco. Biomed Environ Sci 5(1):53–56.